Illinois CancerCare

What Illinois CancerCare does

Illinois CancerCare, P.C. is a private professional corporation headquartered in Peoria, Illinois, operating as one of the largest community oncology and hematology practices in the United States. Founded in 1977 by Dr. Stephen Cullinan, the practice operates 14 clinic locations across Central and Western Illinois, staffed by 22 physicians, 39+ advanced practice providers, 100+ oncology-certified nurses, and more than 500 staff members. The practice serves patients diagnosed with cancer and blood disorders, including benign hematology, and extends services to survivors and individuals with family history of cancer through genetic counseling and testing.

The clinical offering is an integrated oncology stack delivered under one corporate structure: physician-led treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, palliative care), on-site laboratory services (CBC, chemistry, tumor markers, bone marrow biopsy), advanced diagnostic imaging (CT, FDG PET/CT, Pylarify PSMA PET/CT, Copper 64 Dotatate PET/CT, Cerianna PET/CT, X-Ray, DEXA), a URAC-accredited specialty pharmacy with sterile IV compounding and investigational drug services, genetic counseling and testing, oncology counseling, oncology nutrition, and a Cancer SurvivorCare program. The technology infrastructure is conventional healthcare IT — electronic health records, an electronic queue system for patient flow, automated medication management in IV Prep, and a patient portal — with no disclosed AI or machine learning components.

The business model is reimbursement-based, with revenue generated from patient care services billed to commercial insurance, Medicare, and Medicaid, plus prescription fills from the integrated pharmacy and per-enrollment/per-procedure compensation from clinical trial sponsors (NCORP, Sarah Cannon Research Institute, Pfizer, and other pharmaceutical partners). Patient acquisition is driven primarily by physician referrals through a dedicated referral portal, supplemented by self-referrals, second opinions, and community outreach (newsletters, volunteer programs, patient testimonials, and Facebook). Recent strategic moves — the 2024 US Oncology Network partnership (backed by McKesson), the 2025 Sarah Cannon Research Institute partnership, ongoing retail pharmacy expansion, and the first-in-world enrollment on a Pfizer Phase 3 lung cancer trial — signal an intent to scale the community oncology platform while preserving independent physician ownership.

Name

Illinois CancerCare

Legal name

Illinois CancerCare, P.C.

Website

https://illinoiscancercare.com

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

101–250 employees

Short description

Illinois CancerCare is a private community oncology and hematology practice operating 14 clinic locations across Central and Western Illinois with 22 physicians, 39+ advanced practice providers, and 500+ staff, delivering integrated cancer treatment, imaging, lab, pharmacy, and clinical trial services to regional cancer and blood disorder patients.

Ownership category

akta.pro rank

Product category

Oncology and Hematology Care Services

NAICS

Offices of Physicians (62111)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industry

Radiation Oncology (HLAKAFAC)

Keywords

• Oncology treatment services
• Hematology care
• Cancer clinical trials
• Specialty pharmacy services
• Diagnostic imaging oncology

Headquarters

HQ city

Peoria

HQ country

United States

HQ region

North America

Offices13 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Patient Care Services: Revenue generated from comprehensive oncology and hematology treatment services including chemotherapy, targeted therapy, biological therapy, hormonal therapy, diagnostic imaging, laboratory services, and supportive care. Billed through insurance (commercial, Medicare, Medicaid) and patient self-pay.
2. Pharmacy Services: In-house specialty pharmacy providing outpatient prescription medications, clinical pharmacy services, and investigational drug services. Revenue from prescription fills billed to insurance and self-pay patients.
3. Clinical Trial Participation: Revenue from conducting clinical trials in partnership with NCI Community Oncology Research Program (NCORP), Sarah Cannon Research Institute, and pharmaceutical companies. Includes compensation for patient enrollment, study procedures, and drug dispensing.
4. Genetic Testing and Counseling: Genetic counseling and testing services for inherited cancer risk assessment. Revenue from insurance reimbursement and patient self-pay for counseling visits and laboratory testing.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Illinois CancerCare is a private professional oncology and hematology practice delivering comprehensive cancer diagnosis and treatment including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiation oncology consultation. The practice provides integrated in-house specialty pharmacy, advanced diagnostic imaging (CT, FDG PET/CT, PSMA PET/CT, DEXA), on-site laboratory services, and an active clinical trials program with 80-120 active studies at any time. Supporting services include oncology counseling, nutrition programs, genetic testing and counseling, and Cancer SurvivorCare for post-treatment follow-up.

Product overview

Illinois CancerCare is a comprehensive oncology and hematology practice offering a unified suite of cancer and blood disorder care services. The core clinical offerings include Cancer Treatment Services (chemotherapy, immunotherapy, targeted therapy, hormonal therapy), Blood Disorders Treatment, Genetics Clinics, and Pharmacy Services. These are supported by diagnostic services including on-site Laboratory Services and Diagnostic Imaging (CT, PET/CT, X-ray, DEXA). Patient support services encompass Oncology Counseling, Oncology Nutrition Programs, Cancer SurvivorCare, and Drug Therapy Education. The practice operates a robust Clinical Trials Program with partnerships with NCORP and Sarah Cannon Research Institute, offering 100+ active trials. Additional patient-facing services include a Patient Portal, Bill Pay, and a New Patient Video Library. With 14 clinic locations across central Illinois, the practice provides care through 22 physicians, 39+ Advanced Practice Providers, 100+ nurses, and 500+ total staff members.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Treatment Services Comprehensive oncology treatment including chemotherapy, targeted therapy, biological therapy (immunotherapy), hormonal therapy, and palliative care, with personalized treatment plans based on individual cancer biology. For patients diagnosed with cancer across Central and Western Illinois.
• Blood Disorders Treatment Expert hematology care for benign and malignant blood disorders including anemia, platelet disorders, clotting disorders, leukemia, lymphoma, and myeloma, with a specialized Benign Hematology Clinic. For patients with abnormal blood counts or diagnosed blood disorders.
• Genetics Clinics Genetic testing and counseling to identify inherited cancer risks, guide personalized treatment decisions, and support family screening. Includes Lynch syndrome screening and breast cancer risk assessment. For individuals concerned about inherited cancer risk based on personal or family history.
• Pharmacy Services Comprehensive in-house pharmacy comprising URAC-accredited retail specialty pharmacy, IV Prep (sterile compounding), clinical pharmacist services, and investigational drug services for clinical trials. Over 60 staff members support patient medication management across six retail pharmacy locations.
• Oncology Counseling Services Emotional support and guidance for cancer patients and families through individual counseling, support groups (Circle of Support, Gynecological Cancer Support Group), available in-person, virtually, or by phone.
• Oncology Nutrition Programs Registered Dietitian services providing personalized nutrition plans to support healing and manage treatment side effects. Available at no cost to patients and caregivers.
• Laboratory Services On-site laboratory offering comprehensive testing including CBC, chemistry panels, tumor markers, specialized myeloma testing, bone marrow aspiration and biopsy, and therapeutic phlebotomy.
• Diagnostic Imaging Advanced imaging services including CT scans, FDG PET/CT, Pylarify PSMA PET/CT, Copper 64 Dotatate PET/CT, Cerianna PET/CT, Xofigo treatment, X-ray, and DEXA bone density scans at multiple clinic locations.
• Clinical Trials Program Award-winning research program offering 100+ active clinical trials at any given time, with over 14,000 patients enrolled since 1978. Partnerships with NCI Community Oncology Research Program (NCORP) and Sarah Cannon Research Institute.
• Cancer SurvivorCare Post-treatment survivorship program providing ongoing monitoring, management of treatment-related side effects, and coordination with oncologists for long-term health and quality of life. For cancer survivors transitioning from active treatment.
• Patient Portal Online portal allowing patients to view records, manage appointments, and message their care team securely.

Quantifiable outcome

• 14,000+ patients enrolled in clinical trials since 1978
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, flagship and supporting.

• Sarah Cannon Research Institute (SCRI)coreStrategic or Co-development Partner · 1 January 2025In 2025, Illinois CancerCare deepened its research leadership through a partnership with Sarah Cannon Research Institute, one of the world's premier cancer research organizations. This collaboration opens expanded pathways for groundbreaking clinical trials and innovative treatment options, significantly broadening the research portfolio.
• US Oncology Network (USON)flagshipStrategic or Co-development Partner · 1 January 2024In 2024, Illinois CancerCare partnered with the US Oncology Network (USON), supported by McKesson. This landmark partnership elevates the practice's ability to deliver advanced therapies, expand clinical resources, and remain at the forefront of quality community-based cancer care. USON provides access to national resources, research networks, and operational expertise.
• Heartland Cancer Research NCORPcoreStrategic or Co-development Partner · 1 January 2014Illinois CancerCare became a founding member of the Heartland Cancer Research NCI Community Oncology Research Program (Heartland NCORP) in 2014, receiving one of only 37 national NCORP grants. Renewed federal funding through 2025. Illinois CancerCare serves as a core member with Dr. Jane Liu as local principal investigator. The program brings NCI-supported cancer prevention, control, and treatment trials directly to local communities.
• University of ChicagosupportingStrategic or Co-development Partner · 1 January 1994Phase II cancer treatment research affiliation established in 1994, expanding access to innovative clinical trials for local patients through collaboration with the University of Chicago's research program.
• Methodist Medical CentersupportingStrategic or Co-development Partner · 1 January 1983Partnership established in 1983 when Oncology Hematology Associates partnered with Methodist Medical Center to become one of the nation's first Community Clinical Oncology Programs (CCOP), accelerating access to NCI-supported cancer prevention, control, and treatment trials.
• Susan G. Komen Breast CentersupportingStrategic or Co-development PartnerPartnership to improve identification and support of individuals at increased risk for breast and ovarian cancer. Patients are screened for risk level, those identified as moderate or high risk are referred to the genetics team for education, risk management strategies, and personalized care plans.
• Mayo ClinicsupportingStrategic or Co-development PartnerHistorical research partnership established 1978-1979 through the North Central Cancer Treatment Group (NCCTG). Dr. Stephen Cullinan helped establish this groundbreaking partnership. The Illinois Oncology Research Association (IORA) emerged as one of the original NCCTG member institutions.
• OSF HealthcaresupportingChannel Partner/ Reseller/ DistributorPartnership with OSF Healthcare system including OSF Holy Family Medical Center in Monmouth, OSF Saint Francis Medical Center for dietetic internship, and OSF outreach radiation center at Peoria Cancer Center.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• The US Oncology Network: National network of community oncology practices; ILCC joined as a flagship affiliate in 2024. Direct peer in community-based oncology delivery, trial enrollment, and value-based care contracting across multiple U.S. regions.
• Tennessee Oncology: One of the largest independent community oncology practices in the U.S., with comparable scale (multi-site clinics, in-house pharmacy, imaging, clinical trials, genetics). Closely comparable in operating model, talent composition, and value-based care orientation.
• Texas Oncology: Large USON-affiliated community oncology practice with 200+ sites, in-house specialty pharmacy, imaging, and clinical research. Direct comparable in service breadth, geographic distribution, and trial portfolio.
• Florida Cancer Specialists & Research Institute: Large independent community oncology and hematology practice with ~100 sites, in-house specialty pharmacy, central labs, and a top-tier clinical research program. Highly comparable operating model and research scale.
• Minnesota Oncology: Multi-site community oncology and hematology practice offering medical oncology, infusion, imaging, lab, and clinical trials in the Upper Midwest. Comparable mid-size independent practice with research emphasis.
• Regional Cancer Care Associates: Multi-state community oncology practice network with on-site lab, imaging, and clinical trials. Comparable physician-led, multi-site oncology delivery model focused on community access.
• Oncology Hematology Care (OHC): Independent community oncology practice in the Cincinnati region offering medical oncology, hematology, infusion, imaging, lab, and clinical research. Comparable mid-size private practice operating model.

Broad incumbents

• Sarah Cannon Research Institute: One of the largest oncology research organizations in the world; partnered with ILCC in 2025. Broad incumbent in clinical trial management and early-phase oncology research — comparable research depth and pharma-sponsor relationships but at national scale.
• City of Hope: National cancer research and treatment system (formerly including Cancer Treatment Centers of America). Comparable in offering comprehensive oncology, hematology, infusion, imaging, lab, and clinical trials, but at academic/NCI-comprehensive scale vs. ILCC's community setting.

Others

• McKesson / US Oncology Research: Parent organization of the US Oncology Network; ILCC joined as a USON affiliate in 2024. Adjacent enabler providing drug distribution, oncology practice infrastructure, and research support — not a direct operator but a critical ecosystem participant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/IllinoisCancerCarePC
• LinkedInlinkedin.com/company/illinois-cancercare

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Illinois CancerCare